A novel ultra-rare nonsense variant linked to PCDHGC4-related neurodevelopmental disorder in an Iranian patient
Biallelic loss-of-function variants in PCDHGC4 cause a rare autosomal recessive neurodevelopmental disorder characterized by developmental delay or intellectual disability, severe speech impairment, gait abnormalities, and variably microcephaly, seizures, and joint anomalies. The transcript-level consequence of premature termination variants is important because nonsense-mediated mRNA decay (NMD) may preclude production of a stable truncated protein. We clinically evaluated a 9-year-old Iranian Sistani boy and performed whole-exome sequencing followed by Sanger validation and segregation analysis. Variant nomenclature and exon architecture were verified against the MANE Select transcript NM_018928.3. NMD was assessed using canonical exon-junction-complex rules and the UCSC NMDetective-AI track. The patient had moderate intellectual disability, absent speech, esotropic strabismus, delayed walking, and a persistent wide-based unsteady gait, without seizures, microcephaly, or joint hypermobility at the most recent assessment. Brain MRI showed symmetric peritrigonal white-matter hyperintensities without a major structural anomaly. A novel homozygous NM_018928.3:c.1369 C > T variant was identified in PCDHGC4 ; codon-level validation corrected the protein consequence to NP_061751.1:p.(Gln457Ter). The premature termination codon lies in exon 1 of 4, 1071 nucleotides upstream of the first downstream exon-exon junction and 1219 nucleotides upstream of the final junction. Canonical rules therefore predict NMD sensitivity, whereas NMDetective-AI yielded an intermediate/uncertain score (-0.1644), close to its NMD-evading threshold. This additional family expands the phenotypic and allelic spectrum of PCDHGC4 -related neurodevelopmental disorder. The most defensible current mechanism is loss of function, with NMD predicted by the canonical positional rule but not experimentally confirmed. Patient-derived RNA studies are required to determine NMD efficiency and whether any truncated protein is produced.
Authors
- Morteza Oladnabi (ORCID: https://orcid.org/0000-0001-7037-5084)
- Ali Kowsari (ORCID: https://orcid.org/0000-0002-0397-8982)
- Teymoor Khosravi (ORCID: https://orcid.org/0000-0002-4002-2584)
Institutions
- Golestan University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Medical Genomics
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1186/s12920-026-02511-6
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Golestan University of Medical Sciences